Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/2037
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPrince, Miles-
dc.contributor.otherMaqbool, M. Gohar-
dc.contributor.otherTam, Constantine-
dc.contributor.otherMorison, Ian-
dc.contributor.otherSimpson, David-
dc.contributor.otherMollee, Peter-
dc.contributor.otherSchneider, Hans-
dc.contributor.otherChan, Henry-
dc.contributor.otherJuneja, Surrender-
dc.contributor.otherHarvey, Yasmin-
dc.contributor.otherNath, Lakshmi-
dc.contributor.otherHissaria, Pravin-
dc.contributor.otherWordsworth, Helen-
dc.contributor.otherOpat, Stephen-
dc.contributor.otherTalaulikar, Dipti-
dc.date.accessioned2021-11-22T02:32:27Z-
dc.date.available2021-11-22T02:32:27Z-
dc.date.issued2020-02-
dc.identifier.citationPathology. 2020 Feb;52(2):167-178.en_US
dc.identifier.issn0031-3025en_US
dc.identifier.urihttp://hdl.handle.net/11434/2037-
dc.description.abstractWaldenström macroglobulinaemia (WM) is an indolent non-Hodgkin lymphoma which usually presents with symptoms related to infiltration of bone marrow or other tissues like lymph nodes, liver or spleen and has certain unusual clinical manifestations, e.g., renal and central nervous system (CNS) involvement. It also has an array of laboratory features including hypersecretion of IgM, cryoglobulinaemia, increased plasma viscosity and identification of mutated MYD88L265P in more than 90% of cases. In this review, we aim to provide a guide to the laboratory investigations recommended for WM at initial diagnosis and at follow-up. A discussion on the nuances of diagnosis and differential diagnoses is followed by bone marrow (BM) assessment, measurement of paraprotein and other ancillary investigations. Recommendations are provided on laboratory work-up at diagnosis, in the asymptomatic follow-up phase, and during and post-treatment. Finally, we briefly discuss the implications of laboratory diagnosis in regard to recruitment and monitoring on clinical trials.en_US
dc.publisherElsevieren_US
dc.subjectWaldenström Macroglobulinaemia (WM)en_US
dc.subjectLymphoplasmacytic Lymphomaen_US
dc.subjectIgM Paraproteinen_US
dc.subjectImmunoglobulin (Ig) M Monoclonal Gammopathy of undetermined significance (IgM MGUS)en_US
dc.subjectMyeloid Differentiation Primary Response 88 (MYD88)en_US
dc.subjectC-X-C Motif Chemokine Receptor 4 (CXCR4)en_US
dc.subjectCentral Nervous System (CNS)en_US
dc.subjectBone Marrow (BM)en_US
dc.subjectParaproteinen_US
dc.subjectDifferential Diagnosisen_US
dc.subjectFollow-Up Studyen_US
dc.subjectNon-Hodgkin's Lymphomaen_US
dc.subjectEpworth Centre for Immunotherapies and Snowdome Laboratoriesen_US
dc.subjectMolecular Oncology and Cancer Immunologyen_US
dc.subjectCancer Services Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titleA practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.en_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1016/j.pathol.2019.11.002en_US
dc.identifier.journaltitlePathologyen_US
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/31902622en_US
dc.description.affiliatesDepartment of Haematology, ACT Pathology, Canberra Hospital, ACT, Australia; ANU Medical School, College of Medicine and Health, Australian National University, Canberra, ACT, Australiaen_US
dc.description.affiliatesPeter MacCallum Cancer Center, St Vincent's Hospital and University of Melbourne, Melbourne, Vic, Australiaen_US
dc.description.affiliatesSouthern Community Laboratories, Dunedin, New Zealand; Australasian Association of Clinical Biochemists (AACB) Monoclonal Gammopathy Working Group (MGWG), Australiaen_US
dc.description.affiliatesDepartment of Haematology, Waitemata District Health Board, Auckland, New Zealand; Medical and Scientific Advisory Group, Myeloma Australiaen_US
dc.description.affiliatesAustralasian Association of Clinical Biochemists (AACB) Monoclonal Gammopathy Working Group (MGWG), Australia; Medical and Scientific Advisory Group, Myeloma Australia; Department of Haematology, Princess Alexandra Hospital and University of Queensland Medical School, Brisbane, Qld, Australia.en_US
dc.description.affiliatesAustralasian Association of Clinical Biochemists (AACB) Monoclonal Gammopathy Working Group (MGWG), Australia; Alfred Pathology Service and Monash University, Melbourne, Vic, Australia.en_US
dc.description.affiliatesRoyal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Vic, Australia; Pathology Sub-committee of the Lymphoma and Related Diseases Registry (LaRDR), Australiaen_US
dc.description.affiliatesPathology Sub-committee of the Lymphoma and Related Diseases Registry (LaRDR), Australia; Sullivan Nicolaides Pathology, Brisbane, Qld, Australiaen_US
dc.description.affiliatesPathology Sub-committee of the Lymphoma and Related Diseases Registry (LaRDR), Australia; Department of Haematology and Transfusion Medicine, Clinpath Pathology, Adelaide, SA, Australiaen_US
dc.description.affiliatesAustralasian Association of Clinical Biochemists (AACB) Monoclonal Gammopathy Working Group (MGWG), Australia; Royal Adelaide Hospital, University of Adelaide and SA Pathology, Adelaide, SA, Australiaen_US
dc.description.affiliatesMedical and Scientific Advisory Group, Myeloma Australia; Epworth Healthcare, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Vic, Australiaen_US
dc.description.affiliatesPathology Sub-committee of the Lymphoma and Related Diseases Registry (LaRDR), Australia; Department of Haematology, Monash Health, Melbourne, Vic, Australiaen_US
dc.description.affiliatesDepartment of Haematology, ACT Pathology, Canberra Hospital, ACT, Australia; ANU Medical School, College of Medicine and Health, Australian National University, Canberra, ACT, Australia; Medical and Scientific Advisory Group, Myeloma Australia; Pathology Sub-committee of the Lymphoma and Related Diseases Registry (LaRDR), Australiaen_US
dc.type.studyortrialClinical Trialen_US
dc.type.contenttypeTexten_US
Appears in Collections:Cancer Services
MOCI

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.